Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXT3003 Phase III trial in Charcot-Marie-Tooth disease type 1A
NL-OMON52246Phase 3Withdrawn
- Sponsor
- Pharnext
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Charcot-Marie-Tooth disease type 1A (CMT1A) comparing PXT3003 with Placebo (2 arms). Primary endpoint: Change in modified Overall Neuropathy Limitation Scale. Planned start May 2021; status: withdrawn.
02
Drugs
PXT 3003
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on NL-OMON52246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52246.